Real-World Studies
Male Breast Cancer: Clinicopathological Features, Treatment Patterns, and Survival Outcomes
Tepetam et alJournal of Clinical Medicine
A retrospective study from a tertiary referral center evaluated the clinicopathological features, therapeutic patterns, and survival outcomes of 45 men with histopathologically confirmed male breast cancer (MBC) managed between and . Because male breast cancer accounts for less than 1% of all breast malignancies, therapeutic approaches in clinical practice are predominantly extrapolated from female breast cancer trials.
The median patient age at diagnosis was 60 years, with invasive ductal carcinoma identified as the predominant histological subtype in 95.6% of patients. High rates of hormone receptor positivity were observed, with estrogen receptor (ER) expression detected in 93.0% and progesterone receptor (PR) expression in 95.2% of cases, whereas HER2 positivity was present in 26.8%. Treatment patterns reflected standard multimodal approaches: modified radical mastectomy was performed in 95.6% of patients, adjuvant endocrine therapy was administered to 88.9%, adjuvant chemotherapy to 73.3%, and adjuvant radiotherapy to 64.4%.
Over a median follow-up duration of 84 months (range, 1 to 125 months), the estimated 5-year overall survival (OS) reached 85.3% and the 5-year disease-free survival (DFS) was 68.4%. Notably, no locoregional recurrences were documented during follow-up; all observed disease recurrences presented as distant metastatic spread. On univariate Cox proportional hazards regression analysis, none of the examined clinicopathological factors demonstrated a statistically significant association with either OS or DFS. The investigators noted that while contemporary multimodal strategies achieve favorable survival and locoregional control, larger multicenter collaborative trials are required to develop robust prognostic models and generate male-specific prospective evidence.
Key Takeaways
- The estimated 5-year overall survival and disease-free survival rates were 85.3% and 68.4%, respectively, over a median follow-up of 84 months.
- No locoregional recurrences occurred across the entire cohort, with all documented disease recurrences presenting exclusively as distant metastases.
- Tumor profiling showed 93.0% estrogen receptor positivity, 95.2% progesterone receptor positivity, and 26.8% HER2 positivity, though no evaluated clinicopathological variables demonstrated a statistically significant association with overall or disease-free survival.
Read the original sourceJournal of Clinical Medicine
